Skip to main content
search
Conference

2026 ACCP Annual Meeting

Conference: 2026 ACCP Annual Meeting

Date: September 27 - 29, 2026

Location: Bethesda N Marriott Hotel & Conf Ctr N Bethesda, MD

Booth: #2

Certara at the 2026 ACCP Annual Meeting

We are thrilled to participate as an exhibitor at the 2026 American College of Clinical Pharmacology (ACCP) Annual Meeting, held September 27-29, at the Bethesda N Marriott Hotel & Conference Center in North Bethesda, MD.

This year’s theme, “Harnessing changing clinical pharmacology paradigms to improve patient outcomes,” strongly aligns with Certara’s mission to accelerate and improve patient access to innovative therapies through model-informed drug development and regulatory science.

Visit us at Booth #2 to engage with our scientific experts, discover our latest advancements in clinical pharmacology and pharmacometrics, and see how Certara is shaping the future of smarter, faster drug development. We’re proud to showcase our scientific leadership with a substantial presence, including expert-led presentations, scientific posters, and on-site engagement opportunities.

Certara presentations at ACCP 2026

Sunday, September 27 | 1:30 – 5:00 pm | Grand Ballroom A–C
Seminar Symposium 3
Sustainability in the Research and Development of Medicines: An Opportunity for Clinical Pharmacology

Piet van der Graaf, PharmD, PhD
Senior Vice President, Head of Quantitative Systems Pharmacology

Sunday, September 27 | 6:00 pm | Grand Ballroom E–H
Industry Theater Presentation (sponsored by Certara)
Clinical Pharmacology in Global Regulatory Evolution: Single Pivotal Trial for Approval and ICH M15 Implementation

Justin Hay, PhD
Senior Director, Regulatory Strategy and Clinical Pharmacology

This Innovation Theater session examines two major regulatory developments shaping drug development in 2026: the U.S. FDA’s shift toward a single adequate and well-controlled pivotal trial supported by confirmatory evidence, and the implementation of the ICH M15 Guideline on Model-Informed Drug Development (MIDD).

Monday, September 28 | 1:30 – 3:00 pm | Grand Ballroom A–C
Seminar Symposium 6
Pharmacogenetics in Specific Populations: Using Novel Experimental Approaches and Modeling & Simulation to Solve Complex Cases
Relative Impact of CYP2D6 Phenotype on Antidepressant Exposure During Pregnancy and Lactation: Extrapolation Approach Using RWD and PBPK Modelling

Karen Rowland Yeo, PhD
Senior Vice President, Client & Regulatory Strategy

Monday, September 28 | 3:30 – 5:00 pm | Location TBC
Seminar Symposium 8
When Rare Meets Young: Harnessing Clinical Pharmacology to Facilitate Dose Selection and Approval for Pediatric Rare Diseases

Justin Hay, PhD
Senior Director, Regulatory Strategy and Clinical Pharmacology

Explore Certara Resources

We are committed to transforming drug development through innovative science and customer-centric solutions. Learn more about our capabilities:

  • Clinical Pharmacology: Achieve faster, data-driven clinical development decisions with our integrated strategies, from first-in-human to late-phase trials.
  • Pharmacometrics: Uncover actionable insights with industry-leading pharmacometric modeling and exposure-response analyses.
  • Modeling & Simulation Services: Reduce risks and speed up development with robust simulation technologies supporting evidence-based decisions throughout the lifecycle.
  • Simcyp™ PBPK Platform: Confidently predict clinical outcomes using the Simcyp™ PBPK platform for ADME evaluation, drug-drug interactions, and special population responses.
  • Quantitative Systems Pharmacology (QSP): Deepen disease and drug action understanding to enhance target validation and trial design through QSP modeling.
  • Regulatory Science & Strategy: Navigate global regulatory pathways with precision via Certara’s expert-led strategies, submission support, and agency engagement services.

Join us in redefining the future of clinical pharmacology. Stop by Booth #2 or request a meeting with one of our experts. Together, we can optimize therapeutic outcomes and create a positive impact on patient lives.

Request a meeting with our experts


You May Also Like

Enable AI to Access your PK Data: What’s New in Integral 7.1
Enable AI to Access your PK Data: What’s New in Integral 7.1Webinar

Enable AI to Access your PK Data: What’s New in Integral 7.1

Model-Informed Strategies for ADC Development
Model-Informed Strategies for ADC DevelopmentWhite Paper

Model-Informed Strategies for ADC Development

Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers
Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy VolunteersPublication

Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers

Fact Sheet

From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence.

Download now